Learn how ClaimGuardRx addresses both diversion and fraud through a single, conversational platform. Understand why the voice ...
Recognize the role human factors expertise, onboarding, and training and education play in building patient confidence and supporting long-term adherence. Joe Reynolds, Head of User Experience ...
When a drug already sold at a steep 340B discount generates another rebate request, how can manufacturers determine whether ...
Recognize what makes ClaimGuardRx's proprietary, domain-specific LLM different from repurposed fraud tools. Understand how the platform's detect-and-respond design shortens the time between spotting a ...
Aptar Pharma and Aceso Therapeutics team up to advance an inhaled cystic fibrosis therapy, Moonwalk Biosciences raises a $70 ...
An oversubscribed $70 million Series B, co-led by Alpha Wave and YK Bioventures with Eli Lilly participation, funds clinical ...
Our survey findings highlight the critical need for reforms to ensure that IBD patients can access the medications they need ...
Sebastian Arana, head of process solutions at MilliporeSigma, discusses the operational tradeoffs facilities face as they ...
Carelon Research's Mark Cziraky on why analyzing RWD in place — rather than licensing it out — is reshaping how evidence gets ...
Ultragenyx is reviewing program disposition and implementing significant expense reductions as brokerages cut price targets ...
FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results